October 1, 2008 - Finnish Hospital Adopts AutoPulse


A. Ernest Whiton

Chief Financial Officer

ZOLL Medical Corporation

+1 (978) 421-9655



Diane Egan

Kim Angelastro

ZOLL Medical Corporation

Publicis Consultants | PR

+1 (978) 421-9637

+1 (212) 527-8866








October 1, 2008Chelmsford, MASS.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that the Kuopio University Hospital (KUH), one of the largest hospitals in Finland, has successfully implemented the AutoPulse® Non-invasive Cardiac Support Pump in its Intensive Care department. KUH is the first hospital in Finland to establish protocols for using the AutoPulse.


Jouni O. Kurola, M.D., Department of Anesthesiology and Intensive Care, KUH, recommended the implementation following a successful evaluation of an AutoPulse provided to the hospital by ZOLL. “It is remarkable to see how fast our nursing staff adopted the AutoPulse system in our Intensive Care unit,” he said. The AutoPulse gives us the opportunity to provide the best possible care for Sudden Cardiac Arrest (SCA) victims. Our colleagues in Interventional Cardiology have learned from our successes and now use the device as well.”


AutoPulse is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes a wider area of the chest in a consistent, uninterrupted “hands-free” manner, improving blood flow to the heart and brain during cardiac arrest. Additionally, it offers the benefit of freeing up rescuers to focus on other life-saving interventions.


“We’re pleased that Kuopio University hospital, one of the largest and most respected in Finland, has recognized the potential the AutoPulse® has to provide care for SCA victims in their Intensive Care department and Cath Lab by delivering consistent, high-quality chest compressions,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “AutoPulse moves more blood more effectively than manual compressions, thereby providing the best possible patient care.”


To date, approximately 3000 AutoPulse units have been deployed in hospitals and emergency services worldwide.


About Sudden Cardiac Arrest


SCA claims more than 1 million lives each year worldwide. It is the leading cause of unexpected death in the world and strikes without warning. Currently, only about 5 percent of victims survive; 95 percent will die from SCA. SCA is an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs.


About Kuopio University Hospital


Among the providers of specialist health care services in Finland, Kuopio University Hospital (KUH) is one of the largest, and one of the most versatile in its field. Over 3,000 health care professionals provide the services offered by this 800-bed hospital. KUH is internationally recognized for its research work.  It is located in the city of Kuopio, which is the educational, scientific, cultural, commercial and tourism center of Eastern Finland.


Finland has the highest number of people satisfied with their hospital care system in Europe, according to a 2000 survey published by the European Commission. A total of 88 percent of Finnish respondents were satisfied compared with the EU average of 41.3 percent. Finnish health care expenditures are below the European average.


About ZOLL Medical Corporation


ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.


ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. 2008 marks the 25th anniversary of ZOLL’s resuscitation product development. For more information, visit www.zoll.com.


Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 8, 2008. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.


Copyright © 2008 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AED Plus, AutoPulse, LifeBand, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.